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Chaperones play a pivotal role in protein homeostasis, but with age their ability to
clear aggregated and damaged protein from cells declines. Tau pathology is a driver
of a variety of neurodegenerative disease and in Alzheimer’s disease (AD) it appears to
be precipitated by the formation of amyloid-β (Aβ) aggregates. Aβ-peptide appears to
trigger Tau hyperphosphorylation, formation of neurofibrillary tangles and neurotoxicity.
Recently, dihydropyridine derivatives were shown to upregulate the heat shock response
(HSR) and provide a neuroprotective effect in an APPxPS1 AD mouse model. The
HSR response was only seen in diseased cells and consequently these compounds
were defined as co-inducers since they upregulate chaperones and co-chaperones only
when a pathological state is present. We show for compounds tested herein, that they
target predominantly the C-terminal domain of Hsp90, but show some requirement
for its middle-domain, and that binding stimulates the chaperones ATPase activity. We
identify the site for LA1011 binding and confirm its identification by mutagenesis. We
conclude, that binding compromises Hsp90’s ability to chaperone, by modulating its
ATPase activity, which consequently induces the HSR in diseased cells. Collectively,
this represents the mechanism by which the normalization of neurofibrillary tangles,
preservation of neurons, reduced tau pathology, reduced amyloid plaque, and increased
dendritic spine density in the APPxPS1 Alzheimer’s mouse model is initiated. Such
dihydropyridine derivatives therefore represent potential pharmaceutical candidates for
the therapy of neurodegenerative disease, such as AD.
Keywords: Alzheimer’s disease, dementia, neuroprotection, heat shock proteins, dihydropyridine compounds,
heat shock response, Hsp90
INTRODUCTION
The chaperone network helps maintain protein homeostasis (proteostasis) by aiding protein
folding, by clearing aggregated and damaged protein from cells and by maintaining proteins in an
active state (Hartl, 1996; Kim et al., 2013; Penke et al., 2018). However, with age there is a decline in
the capacity of cells to maintain proteostasis and the prevalence of neurodegenerative diseases such
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as Alzheimer’s- (AD) and Parkinson’s-disease increases
(Valastyan and Lindquist, 2014; Toth et al., 2015; Hartl,
2017). Heat shock proteins have been shown to decrease age-
related proteotoxicity, while simultaneously increasing the life
span in organisms such as Caenorhabditis elegans (Murshid et al.,
2013).
The current model of AD suggests that the overexpression
of mutant forms of β-amyloid precursor protein (APP) lead to
amyloid-β (Aβ) plaque and neurofibrillary tangle formation by
Tau (Choi et al., 2015). It is thought that Aβ peptide triggers the
hyperphosphorylation of Tau, a Hsp90 dependent process (Jinwal
et al., 2011), that subsequently leads to neurofibrillary tangles and
neurotoxicity (Hardy and Selkoe, 2002; Selkoe, 2002; Oddo et al.,
2003; Tanzi and Bertram, 2005; Annaert and De Strooper, 2010;
Karran et al., 2011; Benilova et al., 2012). Maintenance of healthy
homeostasis of proteins by modulation of protein processing and
folding systems by chaperone induction represents a prime focus
for drug discovery with AD and neurodegenerative diseases as
key therapeutic targets (Hamos et al., 1991; Alavez et al., 2011).
The accumulation and aggregation of Tau is actually facilitated
by Hsp90, thus increasing its toxicity (Blair et al., 2013). Hence,
there has been a drive to develop Hsp90 inhibitors that promote
the degradation of Tau (Dickey et al., 2007; Luo et al., 2007;
Blair et al., 2014). Small molecules that interfere with the normal
function of Hsp90 are known to induce the heat shock response
(HSR) and increase the degradation of Hsp90 dependent client
proteins such as Tau by a Hsp90-CHIP E3 ubiquitin ligase
dependent pathway (Dickey et al., 2007).
The mechanism of neuroprotective action of dihydropyridine
(DHP) derivatives remains elusive (Kasza et al., 2016), but it
was recently reported that they could activate the HSR (Kasza
et al., 2016). The HSR response was only seen in diseased
cells and consequently these compounds were defined as co-
inducers since they upregulate chaperones and co-chaperones
only in the context of a pathological state (Kasza et al., 2016).
Noteworthy, is that Hsp27 and Hsp70 levels are lower in
the brain of AD patients and consequently the induction of
heat shock proteins represents a potential strategy for the
treatment of neurodegenerative disorders (Klettner, 2004). The
induction of heat shock proteins, such as Hsp27 and Hsp72,
that promote cell survival by preventing protein aggregation and
promoting protein refolding and by eliciting protein degradation
of aggregated proteins (Ehrnsperger et al., 1997), might represent
a novel tool in the treatment of neurodegenerative disease (Söti
and Csermely, 2002; Franklin et al., 2005; Morimoto, 2008;
Manaenko et al., 2010; Tóth et al., 2013; Bobkova et al., 2014;
Eroglu et al., 2014; Kalmar et al., 2014; Wang et al., 2014). This is
all the timelier since the announcement of a variety of clinical trial
failures including those for idalopirdine and intepirdine, selective
5-hydroxytryptamine-6 receptor antagonists, and solanezumab,
an Aβ antibody (Atri et al., 2018; Honig et al., 2018; Simpson,
2018).
The inhibition of Hsp90 is best characterized by binding of
small molecules to its N-terminal ATP binding domain, and
include geldanamycin, radicicol, and synthetic molecules such
as AUY922 (Roe et al., 1999; Brough et al., 2008). Less well
characterized are the C-terminal Hsp90 binding compounds,
including Novobiocin, Coumermycin and KU-32 (Marcu et al.,
2000; Donnelly and Blagg, 2008; Kusuma et al., 2012), and
recently some compounds have emerged as activators of the
ATPase activity of Hsp90. Such compounds include rhamnoside
that are thought to modulate the conformation of Hsp90,
lowering transition states that favor N-terminal dimerization and
therefore ATPase activity (Sattin et al., 2015). Rhamnoside, and
its derivatives (Sattin et al., 2015), were selected initially based
on the stereoelectronic properties displayed by an allosteric site
in the C-terminal domain of Hsp90, which itself was identified
using molecular dynamic simulations (Vettoretti et al., 2016).
Rhamnoside derivatives, which have a benzofuran scaffold at
their core, were later shown to accelerate the Hsp90 cycle and
to stimulate the ATPase activity up to six-fold and to be cytotoxic
against a variety of cancer cell lines (Sattin et al., 2015). Unlike N-
terminal inhibitors, the benzofuran derivatives did not induce the
HSR, but reduced the levels of Hsp90 dependent client proteins
such as ErbB2, Akt, Cdk4, and Survivin (Sattin et al., 2015). In
contrast to activators, a set of structurally-symmetrical chemical
derivatives based on NSC145366, which contains a bisphenol A
core, were shown to be allosteric inhibitors of the ATPase activity
of Hsp90 (Goode et al., 2017). These derivatives compromised
the chaperoning function of Hsp90, by inhibiting its ability to
prevent the aggregation of citrate synthase and the refolding
of luciferase. NSC145366 was particularly active in promoting
androgen receptor and BRAC1 client protein degradation in the
LNCaP androgen sensitive prostate adenocarcinoma cancer cell
line. This inhibitor did not induce the classical HSR seen with N-
terminal inhibitors. To date, and to the best of our knowledge, no
experimentally determined structure of Hsp90 in complex with a
C-terminal binding compound has been reported.
Here we show that DHP derivatives bind to the C-terminal-
and middle-domain of Hsp90 and activate its ATPase activity,
which in turn compromises the chaperone activity of Hsp90.
Through docking studies and mutagenesis, we identify the C-
terminal binding site of DHP derivatives. The molecular basis
for the mechanism by which these DHP derivatives have a
neuroprotective effect in the APPxPS1 Alzheimer’s mouse model
is proposed.
MATERIALS AND METHODS
Protein Purification and Synthesis of
Dihydropyridine Derivatives
pRSETA was used to express yeast full–length Hsp90, human
full-length Hsp90α, Hsp90β and a variety of yeast fragments:
[Hsp901−220 (N-terminal domain), Hsp901−560 (N and middle-
domain), Hsp90273−709 (middle and C-terminal domain),
Hsp90546−709 (C-terminal domain), monomeric yeast Hsp90
(Hsp90F675L,I679M), and human Hsp909−236 (N-terminal
domain)]. Mutants of Hsp90 were generated by Genscript (860
Centennial Ave., Piscataway, NJ 08854, USA). Constructs were
purified by Talon affinity, gel-filtration with an appropriate
molecular mass exclusion, and ion-exchange chromatography as
previously described (Panaretou et al., 1998). The synthesis of
DHP derivatives was previously described (Kasza et al., 2016).
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Isothermal Titration Calorimetry
Heat of interaction was measured on an ITC200
microcalorimeter (Microcal) under the same buffer conditions
(20mM Tris, pH 7.5, containing 1mM EDTA, and 5mM NaCl)
at 30◦C. Either 1.9 or 3.8 µL aliquots of the LA1011, LA1014, or
LA1026 [provided by Gedeon Richter Ltd. (www.richter.hu)] at
1mM were injected into 60µM of Hsp90 protein or a variety
of constructs, including mutants of Hsp90 and complexes of
Hsp90 with 5mM ADP or AMPNP, or Hsp90 complexed with
5mM AMPPNP and 600µM Sba1. 6mM MgCl2 was included
in the buffer in experiments containing nucleotide. Additionally,
3.8 µL aliquots of 90µM Sti1 were injected into 6µM Hsp90
containing 1mM LA1011. 1mM LA1011 was also injected
into 60µM human Hsp72. The concentration of components
used in ITC experiments were based on previous experiments
showing how Hsp90 interacts with nucleotide, Sba1 and Sti1
(Siligardi et al., 2004; Prodromou et al., 2009; Vaughan et al.,
2009). Heats of dilution were determined by diluting injectant
at 30◦C into buffer. Data were fitted using a non-linear least
squares curve-fitting algorithm (Microcal Origin) with three
floating variables: stoichiometry, binding constant (KB = 1/KD)
and change of enthalpy of interaction (1H◦).
ATPase Assays and Gel-Filtration
ATPase assays using 2µM Hsp90 were conducted as previously
described (Prodromou et al., 1999) and displayed a turnover of
1.2 per min. Geldanamycin was prepared at 20mM in DMSO,
whereas 50mM LA1011, LA1014, and LA1026 were soluble in
20mM Tris pH7.5, 1mM EDTA, and 5mM NaCl. Estimation
of the relative molecular mass of wild type Hsp90 and the
monomeric yeast Hsp90F675L,I679M was conducted on a superpose
6 10/300 GL gel-filtration column equilibrated in 20mM Tris pH
7.5, 1mM EDTA, 150mM NaCl, and 1mM DDT.
Citrate Synthase Aggregation Assay
150 nM citrate synthase (2 mg/mL), was incubated at 45◦C for
60min in 1mL of 90mMHEPES buffer containing 20mMKOH,
50mM KCI, 10mM (NH4)2SO4, 2mM potassium acetate, pH
7.8, and Hsp90 at 0, 120, 240, 480, 600, or 1000 nM. Experiments
using 0.1 or 0.2mMLA1011 were conducted with 600 nMHsp90.
The change in optical density was monitored at 320 nm.
Refolding of Denatured Luciferase
QuantiLum Luciferase (Promega E170A) was diluted to 100
ug/mL in 25mM Tricine pH 7.8, containing 10mM MgCl2,
1mM DTT, 0.1mM EDTA, 10% glycerol, and 100 mg/mL
BSA (sigma 05470) and denatured at 44◦C for 30min. 0.5 µL
of denatured luciferase was then added to 20 µL of rabbit
reticulocyte lysate (Promega, L415A) containing either buffer
or LA1011 at 1 or 5mM or geldanamycin at 2.5 or 5µM
and incubated at 30◦C. Geldanamycin was prepared in DMSO
at 0.5 and 2mM and geldanamycin experiments contained a
final DMSO concentration of 1%. Refolding of luciferase was
determined by removing 2 µL aliquots of the rabbit reticulocyte
mix at 0, 15, 30 45, 60, 90, and 120min and adding this to 48 µL
of Briglt-GloTM reconstituted reagent (Promega, E2610), which
contains buffer, substrate and ATP required for luciferase activity,
as instructed by the manufacturer. Luminescence was measured
in a CLARIOstarR microplate reader using half area 96 well flat
bottom plates.
Structural Modeling and Biomolecular
Simulations
HSP90 crystal structures were analyzed and one, an Hsp90α
structure, was selected for docking, based on the regions required
for HSP90 homodimerization (PDB code 3Q6N, 3.05A) (Lee
et al., 2011). The structure was prepared in Schrodinger Suite
2017-3 (Schrodinger LLC, Cambridge, MA 02142, USA) at
pH 7.4 before running a site finding scan. Structure-Activity
Relationship (SAR) and Site Directed Mutagenesis (SDM) data
were used to narrow down the binding pocket, which was then
used as a starting locus for Induced Fit Docking (Glide + Prime
IFD, OPLS 3.0, XP). The Ligand (LA1011) was prepared with
LigPrep at pH 7.4, and a single low energy conformer was
presented for docking. The docking results were compared to
experimental SAR and SDM data and the most reasonable pose
was checked for stability in Molecular Dynamics (Desmond, 100
ns NPT, SPC, 300K). Binding mode analyses were conducted on
the outcomes of the molecular dynamics simulations. PyMol was
used to create cartoon images of the structures1.
RESULTS
Hsp90 Is the Molecular Target of
Dihydropyridine Derivatives
The upregulation of Hsp27, Hsp40 and Hsp70 is a well-
documented response to the perturbation of Hsp90 activity,
resulting from the activation of HSF1 (Heimberger et al., 2013).
We therefore used isothermal titration calorimetry (ITC) to
investigate whether the water-soluble LA1011 drug candidate
would bind Hsp90, thus providing a route by which such
compounds are able to co-induce the HSR. We found that
LA1011 bound to yeast Hsp90 (Kd = 13.5 ± 0.9µM), human
Hsp90α (Kd = 3.8 ± 0.7µM), and human Hsp90β (Kd = 9.7
± 0.7µM) (Figures 1A–C). LA1011 bound Hsp90 with a
small favorable enthalpic and entropic contribution in all cases
(Table 1). The stoichiometry of binding appeared to be one
molecule of LA1011 bound too one Hsp90 dimer, indicating
that binding must occur at a symmetrically located position
along the central long-axis of Hsp90, and it is noteworthy that
LA1011 possesses a plane of symmetry (Figure 2). The degree of
symmetrical interaction with each Hsp90 protomer is, however,
not absolute since LA1014 lacks the symmetry of LA1011, but
non-the-less still bound Hsp90.
To ascertain the stoichiometry of the reaction we investigated
the binding of LA1011 to a monomeric mutant of yeast Hsp90,
that contains two mutations, F675L and I679M that disrupt
dimerization of the C-terminal domains, and no binding was
detected (Figure 1D). We confirmed that this mutant was indeed
monomeric by gel-filtration chromatography (Figure 1E). This
confirmed that LA1011 only binds dimeric Hsp90 and that one
molecule of LA1011 must simultaneously bind to both halves
1The PyMOL Molecular Graphics System, Version 2.0.
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FIGURE 1 | Isothermal titration curves for the binding of LA1011 to a variety of intact chaperone constructs and gel-filtration analysis of Hsp90 monomeric mutant.
(A) yeast full-length; (B) human Hsp90α full-length; (C) human Hsp90β full-length; and (D) yeast monomeric Hsp90F675L,I679M. (E) Gel-filtration profile of wild type
dimeric yeast Hsp90 (blue trace, peak elution volume 13.8ml) and the monomeric mutant Hsp90F675L,I679M (red trace, peak elution volume 14.4ml), showing a
decrease in relative molecular mass of the monomeric mutant Hsp90F675L,I679M mutant. (F) LA1011 binding to human Hsp72. Red lines in ITC figures represent heat
of dilution, while the black fittings represent the corrected heat of interaction for the experiment.
TABLE 1 | Thermodynamic terms for the binding of dihydropyridine derivatives to
Hsp90 constructs.
Protein Compound 1H (cal/mol) 1S (cal/mol/Deg)
Yeast Hsp90 LA1011 −4863 ± 194 6.24
Hsp90α LA1011 −792 ± 80.7 22.2
Hsp90β LA1011 −654.9 ± 43.5 20.8
Yeast 273–709 LA1011 −5110 ± 187 6.07
Yeast 546–709 LA1011 −2603 ± 706 10.7
Yeast 273–709 LA1014 −871.4 ± 145 18.6
Yeast 273–709 LA1026 −1233 ± 210 15.7
Yeast 273–709 represents the middle and C-terminal domains of yeast Hsp90, while Yeast
546–709 represents the yeast C-terminal domain alone.
of the Hsp90 molecule, although the degree of interaction with
each protomer remains unknown. Finally, we tested the ability of
LA1011 to bind human Hsp72 and found that it did not interact
with this chaperone, suggesting that DHP compounds specifically
target the Hsp90 chaperone system (Figure 1F).
LA1011 Binds the C-Terminal Domain of
Hsp90
To determine the exact Hsp90 domain responsible for the
binding of LA1011 we investigated binding to a variety of Hsp90
constructs, including the N-terminal domain of yeast Hsp90
and Hsp90α, Hsp901−560 (representing the N- and middle-
domain of yeast Hsp90), Hsp90273−709 (representing the middle-
and C-domain of yeast Hsp90), and finally a yeast C-terminal
construct, Hsp90546−709. LA1011 failed to bind the isolated N-
terminal domains of yeast and human Hsp90α and a construct
(Hsp901−560) representing the N- and middle-domain of yeast
Hsp90 (Figures 3A–C). In contrast, LA1011 bound with the
same stoichiometry and with a similar affinity to Hsp90273−709,
representing the middle and C-terminal domain construct of
yeast Hsp90 (Kd = 9.7 ± 0.7µM; Figure 3D), as with that seen
for the intact yeast Hsp90 (Kd = 13.5 ± 0.9µM). The binding
affinity was somewhat lower toward the yeast C-terminal domain
alone (Hsp90546−709; Kd = 60.6 ± 7.9µM) (Figure 3E). The
results suggest a single binding site located predominantly in
the C-terminus of Hsp90, which is sufficient for the binding of
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FIGURE 2 | Chemical structure of the synthesized 1,4-dihydropyridine derivatives.
LA1011, but that binding is favored in the presence of the middle
domain. Similarly, LA1014 and LA1026 (Figures 3F,G) bound
yeast Hsp90273−709, but with slightly lower affinity (Kd = 20.2
± 3.0 and 48.8± 4.7µM, respectively). LA1014 and LA1026 also
bound Hsp90273−709 displaying a small favorable enthalpy and
entropy (Table 1).
Nucleotide Effects and Co-chaperone
Binding
We next tested the ability of LA1011 to bind intact yeast
Hsp90 in the presence of ADP or AMPPNP, a non-hydrolysable
analog of ATP. We found that both nucleotides compromised
LA1011 binding, reducing the Kd to approximately 66.2µM
(Figures 4A,B). Interestingly, using a Hsp90-AMPNP-Sba1
complex slightly weakened the binding of LA1011 (Kd = 23.1
± 1.9µM; Figure 4C), relative to wild type yeast Hsp90. Finally,
binding of the yeast co-chaperone Sti1 to Hsp90 was not
compromised by LA1011 (Kd = 0.32 ± 0.01µM) (Figure 4D),
when compared to previous studies showing that Sti1 binds yeast
Hsp90 with a similar affinity (Kd= 0.33± 0.03µM) (Prodromou
et al., 1999). These results indicate that both the closed (AMPPNP
bound) and open (Sti1 bound) conformation of Hsp90 interacts
with LA1011.
LA1011 Is an Activator of the ATPase
Activity of Hsp90
The inhibition of the ATPase activity of Hsp90 by naturally
occurring antibiotics and synthetic molecules is well documented
(Roe et al., 1999; Zhao et al., 2012) and is a known mechanism
for the upregulation of the HSR. Previous attempts to look at
the effects of DHP derivatives on the ATPase activity of Hsp90
suggested that such derivatives did not target Hsp90 (Kasza et al.,
2016). However, the levels of DHP derivatives previously used
were below the Kd values determined in this study. With this
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FIGURE 3 | Isothermal titration curves for the binding of DHPs to a variety of truncated Hsp90 constructs. Binding of LA1011 to (A) yeast Hsp90 N-terminal domain;
(B) Hsp90α N-terminal domain; (C) Hsp901−560 (N and middle domain); (D) Hsp90273−709 (middle and C-terminal domain); and (E) Hsp90546−709 (C-terminal
domain). (F) The binding of LA1014 and (G) LA1026 to the Hsp90273−709 (middle and C-terminal domain). The C-terminal domain appears to be the main site of
interaction for all DHP compounds tested. Red lines in ITC figures represent heat of dilution, while the black fittings represent the corrected heat of interaction for the
experiment.
in mind we tested the effect of these compounds on their ability
to modulate the ATPase activity of Hsp90. Control reactions
with geldanamycin showed inhibition of Hsp90 ATPase activity
(non-inhibited turnover 1.2min), as expected (Figure 5A). In
contrast, LA1011, LA1014, and LA1026 activated the ATPase
activity of yeast Hsp90 (Figures 5B–D). These results suggest that
the ATPase activity of Hsp90 can be allosterically modulated by
the binding of a small molecule to the C-terminal domains of the
chaperone.
LA1011 Compromises Chaperoning by
Hsp90
It has been previously proposed that the C-terminal domain of
Hsp90 is a potential interaction site for client proteins (Harris
et al., 2004). Consequently, DHP derivatives have the potential to
affect the ability of Hsp90 to chaperone such clients.We therefore
investigated whether LA1011 would compromise Hsp90 in
preventing the aggregation of citrate synthase (Figure 6). Based
on theKd of 13µMfor the binding of LA1011 to the yeast protein
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FIGURE 4 | Effect of nucleotide on LA1011 binding and effects on or with co-chaperone interaction. Binding of LA1011 to (A) yeast Hsp90-ADP complex; (B) yeast
Hsp90–AMPPNP complex, and (C) Hsp90-AMPPNP-Sba1 complex. (D) Binding of Sti1 to Hsp90-LA1011 complex. Nucleotide appears to decrease the affinity for
LA1011, while LA1011 has little effect on Sti1 binding itself, based on previous studies (Prodromou et al., 1999). Sba1 weakens LA1011 binding slightly. Red lines in
ITC figures represent heat of dilution, while the black fittings represent the corrected heat of interaction for the experiment.
the fractional occupancy for the binding of LA1011 would be 88–
93%, calculated as [ligand]/[ligand]+Kd, at 0.1–0.2mM LA1011,
respectively. At these concentrations, LA1011 disrupted yeast
Hsp90’s ability to protect citrate synthase from aggregation by
around 50% at 45◦C. This suggests that LA1011 might prevent
access of client protein to Hsp90 or influence its ability to
protect unfolding protein and so interferes with its chaperone
activity.
LA1011 Inhibits the Reactivation of
Denatured Luciferase
To further confirm that LA1011 compromises Hsp90’s ability
to chaperone client protein we used luciferase refolding
in rabbit reticulocyte lysates to investigate its ability to
refold client protein. Based on the Kd of 66µM for the
binding of LA1011 to Hsp90 in complex with AMPPNP,
the fractional occupancy for LA1011 would be 93%,
calculated as [ligand]/[ligand] + Kd, at 1mM LA1011. At
this concentration, LA1011 inhibited Hsp90 by around 50% and
5mM completely prevented refolding of luciferase confirming
that LA1011 compromised the chaperoning function of Hsp90
(Figure 7A). In control assays using geldanamycin we found
that 5µM inhibited luciferase refolding by approximately
50% (Figure 7B). These results are consistent with LA1011
and geldanamycin disrupting the refolding of luciferase
by either directly competing with luciferase binding to
Hsp90 or through perturbation of the Hsp90 chaperone
cycle.
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FIGURE 5 | ATPase assays showing the activation of Hsp90 by DHP derivatives. The turnover for Hsp90 was 1.2 per min. (A) control assay showing the inhibition of
yeast Hsp90 by geldanamycin (Geld). Activation of Hsp90 ATPase activity by (B) LA1011; (C) LA1014, and (D) LA1026. The activated activity can be inhibited by
geldanamycin showing that activation of Hsp90 is specific. Error bars represent standard deviation and assays were carried out in triplicate. Paired t-test was used for
statistical difference. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
Structural Modeling by Docking and
Molecular Dynamics Reveals the
C-Terminal Binding Site
The stoichiometry for the binding of LA1011 was clearly 0.5:1
(Figure 1), representing one LA1011 molecule per Hsp90 dimer.
We used docking studies to test whether this would locate
LA1011 into a site upon the human Hsp90α dimer that was
consistent with this stoichiometry. We found that LA1011 bound
the symmetric dimer of Hsp90 asymmetrically occupying a
single site within the dimer (Figure 8). This was consistent with
the stoichiometric interaction with Hsp90 determined by ITC
(Figure 1).
During the molecular dynamic simulations, as was expected,
the hydrophobic head group of the ligand buried itself into a
hydrophobic ridge, over a hydrophobic cage motif, with the polar
tails being more flexible around the polar side-chains, further
from the interface (Figure 8). Overall, LA1011 sits in amongst
loops connecting the two terminal helices that form the inherent
C-terminal dimer interface of Hsp90, another loop that is formed
by the C-terminal residues 601–632, much of which is disordered,
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FIGURE 6 | Citrate synthase aggregation assays. Increasing concentrations of
yeast Hsp90 prevent citrate synthase aggregation at 45◦C and this activity is
compromised in the presence of LA1011.
and a middle domain loop formed by residues 495–499. The
phenyl ring of LA1011 sits exactly at the center of the dimer
between Ser 677 from each protomer (Figure 8B). This ensures
that only one molecule of LA1011 can bind a single Hsp90 dimer.
The trifluoromethyl group projects into a pocket lined by Leu
672, Leu 678, Pro 681, and the main chain of Phe 676. Potential
hydrogen bonds are formed between the nitrogen atom of the
two ethyldimethylamine groups of LA1011, with either the main-
chain carbonyl of Gly 675 or the main-chain carbonyl of Leu
678. The hydroxyl of Ser 677, potentially, also hydrogen bonds
the carbonyl group of the methyl methanonate. In contrast, the
methyl substituent of the same methyl ethonate group projects
into a hydrophobic pocket lined by the side chains of Leu 672
form each protomer, and those of Leu 678, Pro 681, and His 684.
Mutagenesis Supports the C-Terminal
Binding Site Identified by Docking Studies
In order to validate the C-terminal binding site for LA1011
identified in docking studies we used mutants of Hsp90 that
would interfere with the binding of LA1011. Our model did
not reveal side chain interactions that if mutated would readily
disrupt binding of LA1011. Consequently, we identified residues
that could potentially impact on binding by providing slight
steric hindrance during binding (Figure 9A). Our analysis
suggested that the yeast mutation P661R (P681 in Hsp90α)
would be more disruptive than E477R (E487 in Hsp90α)
and S657R (S677 in Hsp90α). Using ITC, we found that
the Kd for the binding of LA1011 to these mutants was
80.6 ± 19, 26.1 ± 0.9, and 28.6 ± 1.6 µM, respectively
(Figures 9B–D). This is consistent with the predicted effects of
these mutations based on our model and confirms that the C-
terminal site identified by docking studies is the site for LA1011
binding.
FIGURE 7 | Refolding of luciferase. Refolding of luciferase in rabbit reticulocyte
lysate is compromised in the presence of (A) LA1011 and (B) geldanamycin.
Red, control without LA1011, or geldanamycin, blue, 1mM LA1011, or 2µM
geldanamycin and black 5mM LA1011 or 5µM geldanamycin. Errors bars
represent standard error and the experiment was carried out in triplicate.
DISCUSSION
Currently, it is thought that Aβ plaques, formed due
to the aggregation of Aβ-precursor protein, trigger the
hyperphosphorylation of Tau resulting in neurofibrillary tangle
formation and neurotoxicity (Hardy and Selkoe, 2002; Selkoe,
2002; Oddo et al., 2003; Tanzi and Bertram, 2005; Annaert andDe
Strooper, 2010; Jinwal et al., 2011; Karran et al., 2011; Benilova
et al., 2012; Choi et al., 2015). Tau accumulation and aggregation
is facilitated by Hsp90 (Blair et al., 2013), and consequently
efforts are directed toward developing Hsp90 inhibitors that
promote Tau degradation (Dickey et al., 2007; Luo et al., 2007;
Blair et al., 2014). The novel DHP-compounds, LA1011 and
LA1044, were previously shown to act as co-inducers of Hsp70
and Hsp27 in the SH-SY5Y human neuroblastoma cell line
(Kasza et al., 2016). Indeed, LA1011 and LA1044 increase heat
shock protein expression in cells that are stressed or diseased. In
that study the best co-inducer, LA1011, could protect neurons
in the hippocampus, could decrease Tau-accumulation and was
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FIGURE 8 | PyMol cartoons of LA1011 bound to Hsp90. (A) Surface
representation of Hsp90α C-terminal and middle domain regions with LA1011
(yellow sticks) bound at the interface of the two Hsp90 protomers. The
protomers of Hsp90 are green-magenta and cyan-gold, respectively. (B)
PyMol cartoon representation showing the C-terminal and middle domain
residues that were identified as potentially interacting residues with LA1011
through molecular dynamics simulations (residue numbers are for Hsp90α).
LA1011, yellow sticks; cyan residues, C–terminus and middle domain of
Hsp90 protomer 1 and green residues, C–terminus and middle domains of
Hsp90 protomer 2. Blue dashes, potential hydrogen bonds.
able to preserve dendritic spines in the APPxPS1 transgenic
mouse model of AD.
Molecular chaperones together with the ubiquitin-
proteasome system represent a means by which misfolded
proteins in AD could be targeted for clearance (Sulistio and
Heese, 2016) and some heat shock proteins show neuroprotective
action in vivo, (Liu et al., 2009; Manaenko et al., 2010; West
et al., 2012; Doyle et al., 2013; Bobkova et al., 2014; Eroglu
et al., 2014; Cohen et al., 2015). While unregulated HSP
induction could lead to the instability of the HSR (Lamech and
Haynes, 2015), heat shock protein co-inducers, like LA1011,
that specifically target diseased cells would offer a potentially
very useful strategy against neurodegenerative diseases such
as AD. Our investigations herein suggest that the molecular
mechanism by which LA1011 acts is through the modulation
of Hsp90 activity by binding predominantly to its C-terminal
domains. It appears that binding to Hsp90 activates its ATPase
activity and that these compounds appear to bind Hsp90
to both the open (Sti1 bound) and closed conformation of
Hsp90 (Hsp90-AMPPNP). Furthermore, LA1011 binding to
the closed Hsp90-AMPPNP-Sba1 complex was only slightly
affected.
Our results show that the Kd for LA1011 binding to Hsp90 is
in the region of 3.8–13.5µM, which correlates with the 5–10µM
levels of LA1011 that had an effect in mouse models (Kasza et al.,
2016).
However, effects on the in vitro ATPase activity of Hsp90
were much higher. 10µM levels of LA1011 had marginal effects
on the ATPase activity of Hsp90 and levels as high as 240µM
were required to stimulate the ATPase by 2-fold. The reason
for this is that nucleotide (ADP and AMPPNP) influences the
binding of LA1011 reducing its Kd from 13 to 66µM for
yeast Hsp90. While this appears to be a minor change, the
fractional occupancy of the LA1011 binding site would require
0.5mM LA1011 to achieve 88% occupancy in the presence of
ATP, but only 100µM in its absence. These levels of LA1011
correlated well with the levels used in the citrate synthase
aggregation- and luciferase-assay experiments. However, the
difference between in vivo levels (5–10µM) that affect cells
and those required (up to 1mM LA1011) to affect the in vitro
folding of luciferase remains around 100 times different. Such
a difference in the levels of potency of small molecules that
target Hsp90, between in vivo and in vitro experiments, has
previously been reported and differences of up to 100-fold were
seen (Kamal et al., 2003). It appears that in diseased cells Hsp90’s
sensitivity toward small molecules that target Hsp90 is much
greater, but the exact reasons for this remains enigmatic. Finally,
while it is easy to reconcile the effect of inhibition of Hsp90
by compounds such as geldanamycin, which halt chaperone
cycle, and thus prevent protein folding. It is, however, not
so obvious how small molecules that accelerate the chaperone
cycle would have the same effect. Clearly the dwell time of the
cycle must influence the productive folding of a client protein
and, in fact, this has been previously reported (Zierer et al.,
2016).
The mechanism by which the activation of the ATPase activity
of Hsp90 occurs is likely to be similar to rhamnoside, which is
thought to modulate the conformation of Hsp90 by lowering the
transition state that favors N-terminal dimerization and therefore
ATPase activity (Sattin et al., 2015). LA1011 is likely to work
by a similar mechanism and changes in the chaperones rate
might interfere with the mechanism by which client proteins
are folded. For example, it has been seen that downregulating
the ATPase activity of Hsp90, by displacing Aha1 from Hsp90
complex, can rescue misfolding of the delta F508 mutant CFTR
that causes cystic fibrosis. Presumably the mutant CFTR requires
longer to fold than wild type CFTR and benefits from a slower
chaperone cycle or dwell time (Wang et al., 2006). A model by
which proteostasis is maintained by Aha1 regulating the dwell
time of Hsp90 with client has been proposed (Koulov et al., 2010).
The model suggests that Aha1 activity is able to synchronize
chaperone activity with the energetics of client folding by
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FIGURE 9 | Effect of Hsp90 mutants on LA1011 binding. (A) PyMol cartoon showing residues mutated close to the LA1011 binding site and their potential
conformation within the structure. Residues mutated to arginine are shown in gold stick representation. Residue numbers in black are for Hsp90α, while those in red
are for yeast Hsp90. Yellow sticks, LA1011. (B–D) ITC binding curves for LA1011 to the Hsp90 mutants S4657R, P661R, and E477R, respectively. Red lines in ITC
figures represent heat of dilution, while the black fittings represent the corrected heat of interaction for the experiment.
modulating the chaperones ATPase activity. Consequently,
LA1011 is likely to be affecting the synchronization of Hsp90
activity with client protein folding. The degree of effect on client
folding exerted by an increase in the ATPase activity of Hsp90
might, however, depend on the exact client protein in question.
Some clients may be able to tolerate higher rates of Hsp90
activity before their folding is affected, while others may be more
sensitive.
Using molecular dynamics simulations and a variety of
mutant Hsp90 constructs, we were able to confirm the binding
of LA1011 into a pocket formed by a variety of loops from
the C-terminal and middle-domains of Hsp90. The mobility of
such loops could provide a flexible platform for the binding of a
variety of similar compounds that have been shown to bind the
C-terminal domain of Hsp90 (Marcu et al., 2000; Donnelly and
Blagg, 2008; Lee et al., 2011; Kusuma et al., 2012; Sattin et al.,
2015; Vettoretti et al., 2016; Goode et al., 2017), but also the
flexibility to provide binding in both the open and closed states of
Hsp90. It is also noteworthy that the C-terminal domain of Hsp90
has been implicated as a client protein binding site (Genest et al.,
2013) and client protein is known to activate the ATPase activity
of Hsp90 (McLaughlin et al., 2002). Consequently, LA1011 may
be mimicking the binding of a client protein. The flexibility of
this site also raises the possibility that different client protein
sequences might be accommodated. However, the structure of
Hsp90 in complex with Tau has been determined and it doesn’t
appear that Tau, at least, interacts with the C-terminal domain of
Hsp90 (Karagöz et al., 2014).
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Ultimately, whether through competition for client protein
binding or through modulation of Hsp90 activity, there is
upregulation of the HSR that most likely results from the release
of HSF1 from Hsp90 and or because of the higher demand
for Hsp90 in diseased or cell stressed states. This, subsequently
could be beneficial in AD because of increased levels of Hsp70,
Hsp40, and Hsp27 (Heimberger et al., 2013; Blair et al., 2014;
Pratt et al., 2015). Furthermore, the hyperphosphorylation
of Tau, a known Hsp90 dependent process (Jinwal et al.,
2011), may also be disrupted by LA1011, either through direct
competition with Tau for binding to Hsp90 or because the
Hsp90 cycle is dysregulated leading either to increased E3
ubiquitin ligase dependent degradation or reduced levels of
hyperphosphorylation of Tau. However, whichever mechanism
is responsible for the disruption of Tau hyperphosphorylation,
this in turn translates to a decrease in the accumulation of
neurofibrillary tangles and neurotoxicity (Drewes, 2004). Thus,
both elevated chaperone levels, which may aid clearance of Aβ
plaques, and decreased levels of hyperphosphorylated Tau could
be changes in response to LA1011 that are likely to be beneficial
to the prognosis of AD.
The C-terminal domain of Hsp90 has been shown to interact
with nucleotides and it has been proposed that there is a C-
terminal ATP binding site (Marcu et al., 2000; Garnier et al.,
2002). However, structural studies have not revealed the presence
of an obvious ATP binding pocket capable of hydrolyzing ATP
(Ali et al., 2006). It is interesting to note that the binding of
LA1011 in the presence of ADP or AMPPNP was identical
suggesting that these nucleotides influence and weaken the
binding of LA1011 to the same degree. The binding of another
Hsp90 C-terminal inhibitor, C095-0286 was recently modeled
to the yeast C-terminal binding domain (Jiang et al., 2017).
This raises the possibility that the nucleotide and C-terminal
LA1011 binding site are one and the same. If so, it might be
that this site is an adenine nucleotide binding site acting as a
sensor responding to total cellular levels of adenine nucleotide
and/or it might act as a regulatory site with which either co-
chaperones or client proteins are able to interact with. Further
studies will be required to unravel the significance of this
observation. Currently, we are trying to determine a co-crystal
structure to confirm the molecular details of the LA1011 binding
site.
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